JavaScript Required

Jumpseat Aerospace News requires JavaScript to function. Please enable JavaScript in your browser settings to continue.

UK Startup Sends Drug-Making Into Space

May 23, 2026

2 min read

Key Takeaways

BioOrbit sends drug-making technology to space.
Aims to produce self-injected cancer treatment.
Technology enables ultra-pure protein crystals in microgravity.
Could save millions by reducing hospital visits.

Silver membership required Upgrade to Silver to access Key Takeaways.

Upgrade

Strategic Implications

This development may indicate a significant shift in pharmaceutical manufacturing, leveraging microgravity for improved drug formulations. BioOrbit's technology could suggest a new frontier for cancer treatment, potentially transforming the industry and saving healthcare systems millions. The involvement of major investors and partnerships with pharmaceutical companies may indicate a growing interest in space-based manufacturing.

Silver membership required Upgrade to Silver to access Strategic Implications.

Upgrade

What Happened

BioOrbit Develops Technology For Self-Injected Cancer Treatment

A UK startup, BioOrbit, has launched a hi-tech box into space to grow ultra-pure protein crystals for producing self-injected cancer drugs. The technology, developed in London, utilizes the microgravity environment of the International Space Station to enable the crystallization of pharmaceutical compounds. This breakthrough could lead to cancer medications that patients can administer themselves at home, reducing the need for hospital visits. According to The Guardian, BioOrbit’s innovation has the potential to save millions and transform the pharmaceutical industry.

Source

Companies Mentioned